Skip to content


Doptelet (avatrombopag) is a small molecule pharmaceutical. Avatrombopag was first approved as Doptelet on 2018-05-21. It is used to treat thrombocytopenia in the USA. It has been approved in Europe to treat thrombocytopenia. It is known to target thrombopoietin receptor. Doptelet's patents are valid until 2025-05-05 (FDA).
Trade Name Doptelet
Common Name Avatrombopag
Indication thrombocytopenia
Drug Class Thrombopoetin agonists
Get full access now